LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

Kodu・Aktsiate loetelu・Innoviva Inc

Innoviva Inc

Avatud

SektorTervishoid

22.65 1.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.98

Max

22.63

Põhinäitajad
By Trading Economics
Sissetulek	-55M 187M
Müük	-20M 98M
P/E Sektori keskmine	3.436 49.888
Aktsiakasum	0.47
Kasumimarginaal	190.415
Töötajad	159
EBITDA	-160M 48M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+54.5% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-115M 1.6B
Eelmine avamishind	21.08
Eelmine sulgemishind	22.65

Uudiste sentiment

By Acuity

47%

53%

151 / 344 Pingereas Healthcare

Innoviva Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. juuni 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8. juuni 2026, 15:41 UTC

Suurimad hinnamuutused turgudel

American Battery Shares Jump on Energy Department Victory

8. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8. juuni 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Agrees to Buy m3ter

8. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8. juuni 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8. juuni 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8. juuni 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8. juuni 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. juuni 2026, 16:55 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8. juuni 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8. juuni 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8. juuni 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. juuni 2026, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Orange Bought Stake From Lorca

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Acquires 100% Ownership of MasOrange

8. juuni 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8. juuni 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Innoviva Inc Prognoos

Hinnasiht

By TipRanks

54.5% tõus

12 kuu keskmine prognoos

Keskmine 34.5 USD 54.5%

Kõrge 46 USD

Madal 18 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Innoviva Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Innoviva Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.